Dr. Wei Li, MD

Dr. Li practices at Harmony Cardiovascular Care in Flushing, New York.

Dr. Li's NPI, 1780831743, was assigned on August 21, 2008. Dr. Li holds New York license 256795.

Dr. Li's primary practice is Harmony Cardiovascular Care, at 132-37 B 41st Rd, Flushing, NY 11355 in Queens County. The practice phone is (347) 618-1636.

Dr. Li's primary practice is Harmony Cardiovascular Care in Flushing, New York. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Dr. Li to 2 more medical groups, 1 physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Li practices, 2 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Li's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dmand AI has Dr. Li's licenses on file in 4 states: New York, District of Columbia, Florida and Maryland.

CMS data shows 378 Medicare services from Dr. Li across 10 procedure codes in 2024, for 56 Medicare patients. Medicare paid $46,233 for them. Every service was in an office.

CMS counts 56 Medicare patients who saw Dr. Li in 2024. The largest group is 65 to 74, with 28 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Li's median patient age at 59, with 52% women.

In 2024, Dr. Li wrote 1,952 Medicare Part D claims for 176 patients. 85% of them were for generic drugs. CMS names the drug for 1,702 of them, across 38 drugs with 11 or more claims each, at $152,449 in total drug cost. In 2023, CMS named 1,972 claims across 46 drugs.

Dr. Li accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Li as offering telehealth.

CMS Open Payments shows 29 general payments to Dr. Li from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 55% of the total. Endologix, Inc. paid the most, $1,807.